Today I want to discuss a small-cap biopharma name that looks well positioned as a covered call candidate. The options are nicely lucrative and have decent liquidity. The shares have been de-risked by...
Today I want to discuss a small-cap biopharma name that looks well positioned as a covered call candidate. The options are nicely lucrative and have decent liquidity. The shares have been de-risked by...